Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status

Lookup NU author(s): Professor Johannes AttemsORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

PURPOSE: Her-2/neu and p53-mediated signalling have been shown to interact at various cellular levels. However, the clinical relevance of p53 alterations in patients receiving trastuzumab for Her-2/neu-overexpressing metastatic breast cancer (MBC) remains unknown. The present study was performed to corroborate previous in vitro findings from our laboratory showing that trastuzumab induces growth arrest and apoptosis in a p53-independent manner. METHOD: Retrospective immunohistochemical (IHC) analysis for p53 protein expression was carried out on tumour specimens from 104 patients receiving trastuzumab-based treatment for Her-2/neu-overexpressing MBC at a single institution. p53 status was correlated with response (R) and clinical benefit (CB), median progression-free survival (PFS) time and overall survival (OAS) time in univariate and multivariate analyses. RESULTS: Characteristics were similar between p53-negative and p53-positive tumours (all P>0.05). In univariate analyses, R (39% vs 26%, P=0.208), CB (70% vs 57%, P=0.218), PFS (6.2 months vs 4.2 months, P=0.186) and OAS (23.8 months vs 23.2 months, P=0.650) were similar for p53-positive tumours and p53-negative tumours, respectively. In multivariate analyses, p53 status was not a significant predictor of R, CB, PFS or OAS (all P>0.05). CONCLUSIONS: p53 status, as determined by IHC, is not a predictor of the clinical efficacy of trastuzumab-based treatment in patients with Her-2/neu-overexpressing MBC.

Publication metadata

Author(s): Kostler WJ, Brodowicz T, Hudelist G, Rudas M, Horvat R, Steger GG, Singer CF, Attems J, Rabitsch W, Fakhrai N, Elandt K, Wiltschke C, Hejna M, Zielinski CC

Publication type: Article

Publication status: Published

Journal: Journal of Cancer Research and Clinical Oncology

Year: 2005

Volume: 131

Issue: 7

Pages: 420-428

ISSN (print): 0171-5216

ISSN (electronic): 1432-1335

Publisher: Springer

URL: http://dx.doi.org/10.1007/s00432-005-0670-3

DOI: 10.1007/s00432-005-0670-3

Notes: Kostler, Wolfgang J Brodowicz, Thomas Hudelist, Gernot Rudas, Margaretha Horvat, Reinhard Steger, Gunther G Singer, Christian F Attems, Johannes Rabitsch, Werner Fakhrai, Negar Elandt, Katarzyna Wiltschke, Christoph Hejna, Michael Zielinski, Christoph C Comparative Study Germany Journal of cancer research and clinical oncology J Cancer Res Clin Oncol. 2005 Jul;131(7):420-8. Epub 2005 Apr 29.

Altmetrics

Altmetrics provided by Altmetric

Share